Company Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases.
The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
The company was incorporated in 2012 and is based in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Jeffrey Stein |
Contact Details
Address: 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 United States | |
| Phone | 858 752 6170 |
| Website | cidara.com |
Stock Details
| Ticker Symbol | CDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610618 |
| CUSIP Number | 171757107 |
| ISIN Number | US1717571079 |
| Employer ID | 46-1537286 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, Chief Executive Officer and Executive Director |
| Shane M. Ward J.D. | Chief Operating Officer and Corporate Secretary |
| Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer |
| Frank L. Karbe M.B.A. | Chief Financial Officer |
| Dr. Preetam Shah M.B.A., Ph.D. | Principal Accounting Officer |
| Allison Lewis CCP, SPHR | Senior Vice President of People and Culture |
| Dr. Leslie Tari Ph.D. | Chief Scientific Officer |
| Dr. Nicole Davarpanah J.D., M.D. | Interim Chief Medical Officer and Senior Vice President of Translational Research and Development |
| Jim Beitel M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 2, 2025 | 424B3 | Prospectus |
| Dec 31, 2024 | EFFECT | Notice of Effectiveness |
| Dec 30, 2024 | UPLOAD | Filing |
| Dec 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |